Therapy of mild to moderate luminal Crohn's disease.
The management of luminal Crohn's disease, the most common form of initial presentation of the disease, depends on the location and the severity of the lesions. Mild to moderate disease represents a relatively large proportion of patients with a first flare of luminal disease, which may also be associated with perianal disease. As quality of life of these patients correlates with disease activity, adequate therapy is a central goal of the overall patient management. Treatment options include mainly sulfasalazine, budesonide and systemic steroids, while the role of mesalazine and antibiotics remains controversial. The role of biological therapies in mild to moderate disease has not been thoroughly evaluated and will not be discussed here.
Michetti
Pierre
P
Division of Gastroenterology and Hepatology, Lausanne University Medical Center, Lausanne, Switzerland. pierre.michetti@chuv.hospvd.ch
Juillerat
Pascal
P
Mottet
Christian
C
Gonvers
Jean-Jacques
JJ
Burnand
Bernard
B
Vader
John-Paul
JP
Froehlich
Florian
F
Felley
Christian
C
D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003424:Crohn Disease / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D005938:Glucocorticoids